Richard Barry Moss, MD
Pediatric Pulmonology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Moss’s office at (650) 498-5710 to ask if they take your plan before you enroll.
California Medical Board record
Licence G35650 · Current
Licensed to practise in California · since 1977 · expires 2027-10-31 · State University of New York, Downstate Medical Center College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Allergy and Immunology - Allergy and Immunology
- American Board of Pediatrics - Pediatrics
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their 11 Part D prescriptions in 2015. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Year by year
| 2015 | 11 | None | 0% (0) | None | $1,823 |
| 2014 | 14 | None | 0% (0) | 93% | $1,624 |
| 2013 | 16 | None | 0% (0) | 75% | $2,044 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Money from drug and device companies
$4,198 in 2023
| 2023 | 1 | 9 | $1,320 | $4,198 |
| 2019 | 3 | 4 | $1,103 | $1,283 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Astellas Pharma US | Cresemba | $4,198 | 9 payments
|
See all 9 published payments
| Astellas Pharma US | Consulting · 2023-10-23 | Cresemba | $1,320 |
| Astellas Pharma US | Travel · 2023-10-12 | Cresemba | $122 |
| Astellas Pharma US | Travel · 2023-10-11 | Cresemba | $115 |
| Astellas Pharma US | Travel · 2023-10-11 | Cresemba | $115 |
| Astellas Pharma US | Travel · 2023-10-11 | Cresemba | $1,442 |
| Astellas Pharma US | Meals · 2023-10-11 | Cresemba | $47 |
| Astellas Pharma US | Meals · 2023-10-11 | Cresemba | $146 |
| Astellas Pharma US | Travel · 2023-10-10 | Cresemba | $137 |
| Astellas Pharma US | Travel · 2023-10-10 | Cresemba | $755 |
See earlier years (2019)
2019: $1,283
| Regeneron Pharmaceuticals | Dupixent | $784 | 2 payments
|
| Mayne Pharma | Tolsura | $375 | 1 payment
|
| Vertex Pharmaceuticals | None | $124 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| PTC Therapeutics, Inc. · A Phase 3 Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Cystic Fibrosis · 2019 | Their institution | $6,763 |
| PTC Therapeutics, Inc. · A Phase 3 Extension Study of Ataluren in Patients With Nonsense Mutation Cystic Fibrosis · 2019 | Their institution | $4,194 |
Professional record
- NPI
- 1073537528
- Licence
- CA G35650California G35650: Current · expires 2027-10-31
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080P0214X (2080P0214X); Federal specialty code 207K00000X (207K00000X); Federal specialty code 207KI0005X (207KI0005X); Pediatrics (208000000X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2006-07-27
- NPI last updated
- 2024-04-27
- NPI record certified
- 2024-04-27
This is when the NPI record was last certified, not a medical board exam.